1012054-59-9 | CUDC-101

1012920-21-6    1012054-59-9 

[1]Patent:US2009/76022,2009,A1,.Locationinpatent:Page/Pagecolumn68

29823-18-5    1012054-59-9 

[1]Patent:US2009/111772,2009,A1,

[2]Patent:US2009/111772,2009,A1,

905306-05-0    1012054-59-9 

[1]Patent:US2009/111772,2009,A1,

1012057-22-5    1012054-59-9 

[1]Patent:US2009/111772,2009,A1,

1012057-25-8    1012054-59-9 

[1]Patent:US2009/111772,2009,A1,

1012057-21-4    1012054-59-9 

[1]JournalofMedicinalChemistry,2010,vol.53,p.2000-2009

[2]Patent:WO2008/33747,2008,A2.Locationinpatent:Page/Pagecolumn117

[3]Patent:US2009/76022,2009,A1.Locationinpatent:Page/Pagecolumn69-70

[4]Patent:US2009/111772,2009,A1.Locationinpatent:Page/Pagecolumn68

1012054-59-9    74-88-4   

7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-methoxyheptanamide 

[1]Patent:WO2008/33747,2008,A2.Locationinpatent:Page/Pagecolumn151

[2]Patent:US2009/76022,2009,A1.Locationinpatent:Page/Pagecolumn83

[3]Patent:US2009/111772,2009,A1.Locationinpatent:Page/Pagecolumn81

1012054-59-9    2719-27-9    1012054-99-7 

[1]Patent:WO2008/33747,2008,A2.Locationinpatent:Page/Pagecolumn152

[2]Patent:US2009/76022,2009,A1.Locationinpatent:Page/Pagecolumn83

[3]Patent:US2009/111772,2009,A1.Locationinpatent:Page/Pagecolumn82

1012054-59-9    87-69-4   

CUDC-101tartrate 

[1]Patent:US2009/76022,2009,A1.Locationinpatent:Page/Pagecolumn88

Title: A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20150401

Title: Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20141001

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120801

Title: Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.

Journal: Archives of pharmacal research 20120201

Title: Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

Journal: British journal of cancer 20111108

Title: Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?

Journal: Journal of biomedicine & biotechnology 20110101

Title: CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.

Journal: Cancer research 20100501

Title: Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.

Journal: Journal of medicinal chemistry 20100311

Title: Xiong Cai et al Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer J. Med. Chem., 2010, 53 (5), pp 2000–2009

Title: Lai CJ, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.Cancer Res. 2010 May 1;70(9):3647-56. Epub 2010 Apr 13.

Title: Sun H, et al. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. Horm Cancer. 2016 Jun;7(3):196-210.

Title: Zhang L, et al. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget. 2015 Apr 20;6(11):9073-85.